ClinicalTrials.gg
TerminatedNCT05359133Updated Feb 20, 2025

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

A Phase 2 interventional study of Tetrodotoxin and Placebo in Chemotherapy-induced Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by Wex Pharmaceuticals Inc.. Terminated at 15 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Wex Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to lack of funding to continue the study.

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.

Enrollment
1,787th of 2,560
35 · median 66
Started
2022
with 93 others
Phase 2
341 of 2,882
25 open now
Registered
2,356th of 2,882
by date

Among the 2,882 studies in Pain with a site in United States, this one is the 1,787th largest by enrollment of the 2,560 interventional ones that give a count, is one of 94 that started in 2022, is one of 341 in phase 2, and was the 2,356th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

308 more — sign in →

All 313 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,882 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease.

The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.

03

Conditions studied

  • Chemotherapy-induced Neuropathic Pain
  • Chemotherapy-induced Peripheral Neuropathy

Browse trials for

Keywords

  • CINP
  • Chemotherapy-induced Neuropathic Pain
  • Pain
  • Neuropathy
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥21 years.
  • Subjects and their partners must agree to using effective methods of from the time of signature of the form up until 30 days following the end of the Treatment Period.
  • Subjects with neuropathic pain attributed to platinum and/or taxane chemotherapy for a minimum of 3 months duration from screening.
  • Subjects with cancer who have completed a chemotherapy regimen that included taxanes or platinums (or in combination) and have no clinical evidence of actively progressive disease. Subjects must have undergone at least a 90-Day between the last dose of cytotoxic chemotherapy/radiotherapy agent and randomization. Concurrent hormonal therapy and immunotherapy that do not cause neuropathy are permitted.
  • Subjects with a score of 4 or higher out of 10 on the Diagnosing Neuropathic Pain-DN4 Questionnaire (Appendix F) at Screening.
  • Subjects must have at least 10 non-missing scores in the 14 Days prior to randomization during their Baseline Period.
  • Subjects with moderate to severe neuropathic pain that has been stable for 14 Days. Stable pain will be confirmed using an 11-point (0-10) NPRS. To establish moderate or severe stable pain, the average daily pain scores during the 14-Day Baseline Period must be ≥4 with fluctuation in the daily pain score of ≤2 points in increase or decrease. Subjects with an average pain score >9 at Baseline will be excluded.
  • Subjects with an Performance Status score of 0 or 1 (Oken et al, 1982).
  • Subjects who are able to communicate well with the trial staff and to comply with the trial requirements (restrictions, appointments, and examination schedule).
  • Subjects who are able to complete the trial-related questionnaires independently in either English or in the local language.
  • Subjects who sign an informed consent document (prior to the performance of any trial related procedures).

Exclusion criteria

Exclusion Criteria:

  • History of peripheral neuropathy attributed to any cause other than platinum or taxane chemotherapy (e.g., radiotherapy, vinca alkaloids, diabetes, alcohol, toxin, hereditary, , or severe malnutrition).
  • Subjects who have received TTX at any time prior to enrolment.
  • Subjects receiving agents known to cause peripheral neuropathy within 90 Days of randomization.
  • Current use of any other therapy (including alternative nonmedical therapy) for the treatment of neuropathic pain within 60 Days of randomization unless the dose is stable for the 60 Days immediately prior to randomization. Subjects who fail this criterion can be rescreened after 60 Days of stability.
  • Current use of opioids or plans to start using opioids during the study period. However, opioids at doses of ≤90 mg morphine equivalents per day are permitted as long as subject is on stable dose for at least 60 days prior to randomization and plan on staying on that stable dose (fixed dose and schedule) throughout the study.
  • Subjects who require rescue medication for breakthrough pain with medication other than acetaminophen or Ibuprofen. Before and after randomization, acetaminophen will be allowed at doses up to 2600 mg per day \<3 times a week or Ibuprofen will be allowed at doses up to 1200 mg per day \<3 times a week.
  • Any concomitant medication that prolongs the or QRS interval unless on a stable dose for 60 Days prior to randomization.
  • Subjects with known impaired renal function as determined by a screening serum creatinine >1.5x normal.
  • Subjects who have not recovered from all toxicities related to chemotherapy to \< grade 1 or mild AE's with the exception of CINP.
  • Subjects who have inadequate organ function tests including: \< 10 g/dl; ANC \< 1500/µL; Plt. count \< 100,000/µL; liver function ( and/or AST) more than 2 times the .
  • Subjects with urinary retention.
  • Subjects with documented bone at the time of trial entry.
  • Subjects with predicted of \<8 months.
  • Subjects scheduled for chemotherapy or radiotherapy between Screening and the End of Trial visit (Week 13).
  • Current use of lidocaine (including Lidoderm) and other types of sodium channel antiarrhythmic drugs within 30 Days of randomization.
  • Subjects who have been injected with Botulinum toxin (e.g., Botox®) in the 3 months prior to randomization, or who plan to receive a Botulinum toxin injection during the study period.
  • Subjects who require regular antiemetic medication.
  • Current use of tricyclic antidepressant medication, anticonvulsants, or monoamine oxidase inhibitors. Stable use of those medications for at least 2 months is permissible if the subject has qualifying pain and plans to remain on a stable dose throughout the trial.
  • Subjects will be excluded if they have a current diagnosis of uncontrolled Major Depressive Disorder.
  • Subjects with current uncontrolled asthma, carbon dioxide retention, or oxygen saturation \<92% on room air, or require oxygen therapy at any concentration.
  • Subjects with second- or third-degree heart block or prolonged QTc interval (corrected for rate) on screening (ECG) (i.e., confirmed >450 msec for men and >470 msec for women on repeated occasion) or any other active cardiac arrhythmia or abnormality that might constitute a clinical risk.
  • Subjects with neuromuscular conditions, including but not limited to any impairment that influence swallowing or breathing function.
  • Use of an agent within 30 Days prior to Screening or scheduled to receive an investigational drug other than TTX during the course of the trial.
  • History of alcoholism, or current intake deemed excessive by the investigator or routine use averaging >3 units of alcohol per day.
  • Active substance abuse or drug dependency in the opinion of the investigator, including prescription drug abuse.
  • Women who are pregnant or breast feeding.
  • Any other condition that in the opinion of the investigators is likely to interfere with treatment, impede data collection, or that poses a risk to the subject.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Active comparator
    Tetrodotoxin for injection

    30 µg, 1 ml SC injection in the thigh or abdomen, twice daily for 4 Days

    Drug: Tetrodotoxin

  • Placebo comparator
    Placebo

    1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days

    Drug: Placebo

Interventions

  • TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5

    Also known as: Halneuron

  • DrugPlacebo

    Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug. Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle.

    Also known as: Sterile 0.9% sodium chloride injection

06

What researchers measure

Primary outcomes

  1. NPRS Pain reduction - at week 4

    The Change from Baseline (average of Days -14 to -1) at Week 4 in average weekly NPRS scores in subjects treated with TTX compared to Placebo

    Time frame: At week 4

Secondary outcomes

  1. NPRS Pain reduction - at week 8

    The Change from Baseline (average of Days -14 to -1) at Week 8 in average weekly NPRS scores in subjects treated with TTX compared to Placebo

    Time frame: At week 8

  2. NPRS Pain reduction - at week 12

    The Change from Baseline (average of Days -14 to -1) at Week 12 in average weekly NPRS scores in subjects treated with TTX compared to Placebo

    Time frame: At week 12

Other outcomes

  1. AUC up to week 12

    AUC calculated on the Change from Baseline through Week 12 in weekly average NPRS scores.

    Time frame: baseline to week 12

  2. NPRS Pain reduction - weekly

    Change from Baseline to each study week through Week 12 in Average Weekly NPRS scores

    Time frame: baseline to week 12

  3. NPRS Pain reduction - weekly

    Percent Change from Baseline to each study week through Week 12 in Average Weekly NPRS scores

    Time frame: baseline to week 12

  4. Subjects with at least 30% reduction in pain

    Proportion of responders at Week 12, defined as subjects showing a 30% or greater reduction from overall Baseline (Week -1 \& week -2) to Week 12 in weekly average NPRS score.

    Time frame: baseline to week 12 (assessed weekly)

  5. Subjects with at least 50% reduction in pain

    Proportion of responders at Week 12, defined as subjects showing a 30% or greater reduction from overall Baseline (Week -1 \& week -2) to Week 12 in weekly average NPRS score.

    Time frame: baseline to week 12 (assessed weekly)

  6. Time to response

    Time to first response defined as (30%/50%) reduction from overall Baseline in weekly average NPRS score

    Time frame: Day 1 to week 12

  7. Duration of response

    Duration of response defined as time from initial (30%/50%) reduction from overall baseline in weekly average NPRS score to first loss of response.

    Time frame: Day 1 to week 12

  8. BPI change

    Change from Baseline to each study visit through Week 12 in quality of life and pain intensity measures using the Brief Pain Inventory (BPI).

    Time frame: Baseline to Week 12

  9. NPSI change

    Change from Baseline to each study visit through Week 12 in neuropathic pain symptoms using the Neuropathic Pain Symptoms Inventory (NPSI)

    Time frame: Baseline to Week 12

  10. POMS change

    Change from Baseline to each study visit through Week 12 in Profile of Mood States (POMS2) total mood disturbance, and each of the 6 specific subscales.

    Time frame: Baseline to Week 12

  11. Percent of subjects taking Rescue Medication

    Percentage of subjects taking allowed and prohibited rescue medication at each week, including Week 12.

    Time frame: Baseline to Week 12

  12. Average rescue medication consumed

    Average per-subject consumption of allowed and prohibited rescue medication at each week, including Week 12

    Time frame: Baseline to Week 12

  13. Patient global impression of change questionnaire

    Subjects' Global Impression of Change responses at each visit through the End-of-Trial visit.

    Time frame: at week 12

  14. Proportion of responders (30%/50%)

    Proportion of responders (30%/50%) at each study week through Week 12

    Time frame: weekly until week 12

07

Study locations

15 sites
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
  • MEDSOL Clinical Research Center
    Port Charlotte, Florida 33952, United States
  • Care Access Research
    Macon, Georgia 31201, United States
  • Paradigm Clinical Research
    Boise, Idaho 83709, United States
  • Clinical Trials of SWLA
    Lake Charles, Louisiana 70601, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • St Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Care Access Research
    Clifton, New Jersey 07013, United States
  • ES Clinical Research Group
    Garden City, New York 11530, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Oncology Specialists of Charlotte
    Charlotte, North Carolina 28207, United States
  • Oklahoma Cancer Specialists and Research Institute (OCSRI)
    Tulsa, Oklahoma 74146, United States
  • Center for Oncology and Blood Disorders (COBD)
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Oct 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2022
First posted
May 3, 2022
StartActual
Apr 19, 2022
Primary completionActual
Oct 14, 2024
CompletionActual
Oct 14, 2024
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05359133
Lead sponsor
Wex Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Apr 19, 2022
Primary completion
Oct 14, 2024
Completion
Oct 14, 2024
Last update
Feb 20, 2025

Study contacts

Walter Korz
study director · COO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tetrodotoxin

Start the discussion